Search Results - "Quinn, Katie"

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project by Merino, Diana M, McShane, Lisa M, Fabrizio, David, Funari, Vincent, Chen, Shu-Jen, White, James R, Wenz, Paul, Baden, Jonathan, Barrett, J Carl, Chaudhary, Ruchi, Chen, Li, Chen, Wangjuh (Sting), Cheng, Jen-Hao, Cyanam, Dinesh, Dickey, Jennifer S, Gupta, Vikas, Hellmann, Matthew, Helman, Elena, Li, Yali, Maas, Joerg, Papin, Arnaud, Patidar, Rajesh, Quinn, Katie J, Rizvi, Naiyer, Tae, Hongseok, Ward, Christine, Xie, Mingchao, Zehir, Ahmet, Zhao, Chen, Dietel, Manfred, Stenzinger, Albrecht, Stewart, Mark, Allen, Jeff

“…BackgroundTumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive…”
Get full text

Cell-cycle dependence of transcription dominates noise in gene expression by Zopf, C J, Quinn, Katie, Zeidman, Joshua, Maheshri, Narendra

“…The large variability in mRNA and protein levels found from both static and dynamic measurements in single cells has been largely attributed to random periods…”
Get full text

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer by Aggarwal, Charu, Thompson, Jeffrey C, Chien, Austin L, Quinn, Katie J, Hwang, Wei-Ting, Black, Taylor A, Yee, Stephanie S, Christensen, Theresa E, LaRiviere, Michael J, Silva, Benjamin A, Banks, Kimberly C, Nagy, Rebecca J, Helman, Elena, Berman, Abigail T, Ciunci, Christine A, Singh, Aditi P, Wasser, Jeffrey S, Bauml, Joshua M, Langer, Corey J, Cohen, Roger B, Carpenter, Erica L

“…The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic…”
Get full text

A dataset quantifying polypharmacy in the United States by Quinn, Katie J., Shah, Nigam H.

“…Polypharmacy is increasingly common in the United States, and contributes to the substantial burden of drug-related morbidity. Yet real-world polypharmacy…”
Get full text

Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study by Scott, Madeleine K D, Quinn, Katie, Li, Qin, Carroll, Robert, Warsinske, Hayley, Vallania, Francesco, Chen, Shirley, Carns, Mary A, Aren, Kathleen, Sun, Jiehuan, Koloms, Kimberly, Lee, Jungwha, Baral, Jessika, Kropski, Jonathan, Zhao, Hongyu, Herzog, Erica, Martinez, Fernando J, Moore, Bethany B, Hinchcliff, Monique, Denny, Joshua, Kaminski, Naftali, Herazo-Maya, Jose D, Shah, Nigam H, Khatri, Purvesh

“…There is an urgent need for biomarkers to better stratify patients with idiopathic pulmonary fibrosis by risk for lung transplantation allocation who have the…”
Get full text

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study by Si, Han, Kuziora, Michael, Quinn, Katie J, Helman, Elena, Ye, Jiabu, Liu, Feng, Scheuring, Urban, Peters, Solange, Rizvi, Naiyer A, Brohawn, Philip Z, Ranade, Koustubh, Higgs, Brandon W, Banks, Kimberly C, Chand, Vikram K, Raja, Rajiv

“…Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non-small cell lung cancer (NSCLC) treated with immune…”
Get full text

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer by Jacobs, Samuel A, Wang, Ying, Abraham, Jame, Feng, Huichen, Montero, Alberto J, Lipchik, Corey, Finnigan, Melanie, Jankowitz, Rachel C, Salkeni, Mohamad A, Maley, Sai K, Puhalla, Shannon L, Piette, Fanny, Quinn, Katie, Chang, Kyle, Nagy, Rebecca J, Allegra, Carmen J, Vehec, Kelly, Wolmark, Norman, Lucas, Peter C, Srinivasan, Ashok, Pogue-Geile, Katherine L

“…We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer…”
Get full text

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer by Jacobs, Samuel A, Wang, Ying, Abraham, Jame, Feng, Huichen, Montero, Alberto J, Lipchik, Corey, Finnigan, Melanie, Jankowitz, Rachel C, Salkeni, Mohamad A, Maley, Sai K, Puhalla, Shannon L, Piette, Fanny, Quinn, Katie, Chang, Kyle, Nagy, Rebecca J, Allegra, Carmen J, Vehec, Kelly, Wolmark, Norman, Lucas, Peter C, Srinivasan, Ashok, Pogue-Geile, Katherine L

Get full text

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors by Vega, Diana Merino, Nishimura, Katherine K, Zariffa, Névine, Thompson, Jeffrey C, Hoering, Antje, Cilento, Vanessa, Rosenthal, Adam, Anagnostou, Valsamo, Baden, Jonathan, Beaver, Julia A, Chaudhuri, Aadel A, Chudova, Darya, Fine, Alexander D, Fiore, Joseph, Hodge, Rachel, Hodgson, Darren, Hunkapiller, Nathan, Klass, Daniel M, Kobie, Julie, Peña, Carol, Pennello, Gene, Peterman, Neil, Philip, Reena, Quinn, Katie J, Raben, David, Rosner, Gary L, Sausen, Mark, Tezcan, Ayse, Xia, Qi, Yi, Jing, Young, Amanda G, Stewart, Mark D, Carpenter, Erica L, Aggarwal, Charu, Allen, Jeff

“…As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies…”
Get more information

Hierarchical scaffolds via combined macro- and micro-phase separation by George, Peter A, Quinn, Katie, Cooper-White, Justin J

“…Abstract Recent advances in biomaterial surface engineering have shown that surface biomechanical, spatial and topographical properties can elicit control over…”
Get full text

33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis by Gordon, Sean, Pellini, Bruna, Barnett, Reagan, Liao, Jiemin, Quinn, Katie, Wienke, Sara, Drusbosky, Leylah, Zhang, Nicole, Lefterova, Martina, Lawrence, Lauren, Kiedrowski, Lesli, Eppler, Ross, Odegaard, Justin, Chuang, Han-Yu

“…BackgroundStudies have shown that high TMB (≥10mut/MB on tissue) across solid tumors is associated with improved overall survival (OS) in patients (pts)…”
Get full text

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy by Lee, Jii Bum, Park, Hyung Soon, Choi, Su Jin, Heo, Seong Gu, An, Ho Jung, Kim, Hye Ryun, Hong, Min Hee, Lim, Sun Min, Chang, Kyle, Quinn, Katie, Odegaard, Justin, Shim, Byoung Yong, Cho, Byoung Chul

“…Background: The clinical utility of plasma tumor mutational burden (pTMB) requires further validation. Herein, the pTMB and genetic alterations were…”
Get full text

Study protocol for autism specific transition resources (T-Res Study): developing a flexible resource package for dealing with the loosening and/or lifting of COVID-19 related restrictions by Smyth, Sinéad, Mc Laughlin, Nadine, Egan, Cillian, Gurrin, Cathal, Quinn, Katie, McGarrell, Maria, Devlin, Sarah

“…Autism specific transition resources (T-Res) aims to develop a flexible resource package to support children and young people with a diagnosis of autism…”
Get full text

Reply – “Letter to the Editor–Very-low calorie diet and Semaglutide: Synergy and long-term impact on type 2 diabetes management” by Anyiam, Oluwaseun, Phillips, Bethan, Quinn, Katie, Wilkinson, Daniel, Smith, Kenneth, Atherton, Philip, Idris, Iskandar

Get full text

Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus by Anyiam, Oluwaseun, Phillips, Bethan, Quinn, Katie, Wilkinson, Daniel, Smith, Kenneth, Atherton, Philip, Idris, Iskandar

“…Very-low calorie diets (VLCD) and the glucagon-like peptide-1 receptor agonist (GLP1RA) Semaglutide induce significant weight loss and improve glycaemic…”
Get full text

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer by Topham, James T, O'Callaghan, Chris J, Feilotter, Harriet, Kennecke, Hagen F, Lee, Young S, Li, Weimin, Banks, Kimberly C, Quinn, Katie, Renouf, Daniel J, Jonker, Derek J, Tu, Dongsheng, Chen, Eric X, Loree, Jonathan M

“…Anti-epidermal growth factor receptor (EGFR) antibodies are effective treatments for metastatic colorectal cancer. Improved understanding of acquired…”
Get full text

Addition of very low calorie diet (VLCD) during initiation of semaglutide in individuals with type 2 diabetes – interim results by Anyiam, Oluwaseun, Quinn, Katie, Phillips, Bethan, Wilkinson, Daniel, Smith, Kenneth, Atherton, Philip, Idris, Iskandar

Get full text

The Effect of False Positive Feedback on Learning an Inhibitory-Action Task in Older Adults by Grealy, Madeleine A., Cummings, Joanne, Quinn, Katie

“…Background/Study Context: Older adults show a greater response to feedback whilst learning than younger adults. To date this has only been shown for receiving…”
Get full text

Abstract 401: Comparison of molecular response calculations for prediction of patient outcome by Mak, Allysia J., Quinn, Katie J., Espenschied, Carin, Chang, Kyle, Chuang, Han-Yu, Helman, Elena, Chudova, Darya, Odegaard, Justin, Nagy, Becky, Talasaz, AmirAli

“…Abstract Background: Molecular response (MR) estimated as a change in circulating tumor (ctDNA) load between an early on treatment sample (usually 2-9 weeks…”
Get full text

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial by Loree, Jonathan M, Titmuss, Emma, Topham, James T, Kennecke, Hagen F, Feilotter, Harriet, Virk, Shakeel, Lee, Young S, Banks, Kimberly, Quinn, Katie, Karsan, Aly, Renouf, Daniel J, Jonker, Derek J, Tu, Dongsheng, O'Callaghan, Chris J, Chen, Eric X

“…Tissue-derived tumor mutation burden (TMB) of ≥10 mutations/Mb is a histology-agnostic biomarker for the immune checkpoint inhibitor (ICI) pembrolizumab…”
Get full text